We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
-6.02%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$244M
AUM Growth
-$94.8M
Cap. Flow
-$73.9M
Cap. Flow %
-30.28%
Top 10 Hldgs %
68.7%
Holding
38
New
11
Increased
8
Reduced
2
Closed
17

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$21.9M
2
ABBV icon
AbbVie
ABBV
+$18.8M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
4
AMGN icon
Amgen
AMGN
+$11.3M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.6M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$30.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$29.7M
3
A icon
Agilent Technologies
A
+$17.9M
4
LEGN icon
Legend Biotech
LEGN
+$15.9M
5
LLY icon
Eli Lilly
LLY
+$15.3M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
26
BioCryst Pharmaceuticals
BCRX
$2.29B
– –
-798,137
Closed -$6.07M
BMY icon
27
Bristol-Myers Squibb
BMY
$135B
– –
-574,057
Closed -$29.7M
ELVN icon
28
Enliven Therapeutics
ELVN
$4.37B
– –
-207,896
Closed -$5.31M
GILD icon
29
Gilead Sciences
GILD
$168B
– –
-359,025
Closed -$30.1M
HRMY icon
30
Harmony Biosciences
HRMY
$2.25B
– –
-376,315
Closed -$15.1M
IONS icon
31
Ionis Pharmaceuticals
IONS
$9.15B
– –
-97,300
Closed -$3.9M
IOVA icon
32
Iovance Biotherapeutics
IOVA
$1.95B
– –
-876,009
Closed -$8.23M
JAZZ icon
33
Jazz Pharmaceuticals
JAZZ
$16.4B
– –
-117,500
Closed -$13.1M
LEGN icon
34
Legend Biotech
LEGN
$3.7B
– –
-325,953
Closed -$15.9M
LLY icon
35
Eli Lilly
LLY
$995B
– –
-17,299
Closed -$15.3M
NTLA icon
36
Intellia Therapeutics
NTLA
$1.58B
– –
-390,622
Closed -$8.03M
RNAM
37
DELISTED
Avidity Biosciences
RNAM
– –
-160,947
Closed -$7.39M
SWTX
38
DELISTED
SpringWorks Therapeutics
SWTX
– –
-378,453
Closed -$12.1M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Cutter Capital Management held 38 positions worth $244M, down 28% from $339M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Cutter Capital Management withdrew a net $73.9M in Q4 2024, closing 17 positions and reducing 2 holdings. Its most notable exit was Gilead Sciences, an estimated $30.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Cutter Capital Management opened a new position in Johnson & Johnson worth $20.5M.

  • Cutter Capital Management's largest Q4 2024 buy was Johnson & Johnson: 141,572 shares worth $20.5M.
  • Cutter Capital Management added most to Regeneron Pharmaceuticals in Q4 2024, an estimated $14.3M increase.
  • Cutter Capital Management's biggest Q4 2024 reduction was Perrigo, cutting an estimated $6.92M.
  • Cutter Capital Management fully exited Gilead Sciences in Q4 2024, selling an estimated $30.1M.
  • Cutter Capital Management's ten largest holdings make up 69% of its $244M portfolio in Q4 2024.
  • Cutter Capital Management opened 11 new positions and closed 17 in Q4 2024.
  • Cutter Capital Management's portfolio value fell 28% quarter-over-quarter to $244M.

Based on Cutter Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.